ERBB2 and breast carcinoma: Indeed, MET is overexpressed in about 40% of breast cancer patients (in luminal A: 36%; in Luminal B: 39%; in HER2+: 48%; in TNBC: 53%[56]), and its overexpression often correlates with poorly differentiated and aggressive forms of the disease.[41] In TNBC, MET is particularly highly expressed, and implicated in malignancy progression (Figure S7, Supporting Information), metastasis, and resistance to anticancer therapies.[40, 41] Consequently, agents targeting MET are actively being explored for clinical purposes,[57, 58] including in TNBC.[59, 60, 61]